Community Clinical Oncology Program
NCI invites domestic institutions to apply for cooperative agreements in response to this Community Clinical Oncology Program (CCOP) RFA. Applicants for new and currently funded CCOPs and research bases may respond. This reissuance of RFA-CA-04-008 seeks to build on the strength and success of the network over the past 20 years by continuing to support community participation in cancer treatment, prevention, and control clinical trials through research bases; expanding and strengthening the cancer prevention and control research effort; utilizing the CCOP network for conducting NCI-assisted cancer prevention and control research; and evaluating CCOP performance and impact in the community.
The RFA will use the NIH U10 award mechanism.
For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2040
Inquiries: Dr. Lori Minasian, firstname.lastname@example.org
Minority-Based Community Clinical Oncology Program
NCI is continuing the established cancer control effort involving oncologists who serve large minority populations in the NCI clinical trials program, providing a network of support for clinical research in cancer centers, major university centers, and community programs. Domestic institutions with the capability and intent to serve new cancer patients largely from minority populations are invited to apply for cooperative agreements in response to this Minority-Based Community Clinical Oncology Program (CCOP) Request for Applications (RFA). Currently funded Minority-Based CCOPs are also invited to respond.
This RFA will use the NIH U10 award mechanism.
For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2041
Inquiries: Dr. Worta McCaskill-Stevens, email@example.com
Support for Human Specimen Banking in NCI-Supported Cancer Clinical Trials
The purpose of this initiative is to support the infrastructure needed to ensure the collection of, storage of, and access to high-quality, well-annotated human specimens collected from and representative of the patient populations entered into NCI-funded, phase III clinical treatment trials.
The RFA will use the NIH U24 Cooperative Agreement award mechanism for Resource-Related Research Projects.
For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2043
Inquiries: Dr. Roger L. Aamodt, firstname.lastname@example.org
Community Networks to Reduce Cancer Health Disparities
NCI, through its Center to Reduce Cancer Health Disparities (CRCHD), invites cooperative agreement grant applications for Community Networks to Reduce Cancer Health Disparities Through Education, Research, and Training (Community Networks Program, CNP). The purpose of the CNP is to reduce cancer health disparities by conducting community-based participatory education, training, and research among racial/ethnic minorities and underserved populations. The overall goals of this program are to significantly improve access to and utilization of beneficial cancer interventions in communities with cancer health disparities, thereby reducing these disparities. This RFA is a reissue of RFA-CA-99-003.
The RFA will use the NIH cooperative agreement U01 award mechanism.
For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2042
Inquiries: Dr. Kenneth C. Chu, KC10D@NIH.GOV
Paul Calabresi Award for Clinical Oncology (K12)
The purpose of the Paul Calabresi Award for Clinical Oncology is to increase the number of medical doctors and doctorally degreed nurses and basic scientists who are highly motivated and trained to: (1) perform clinical oncology therapeutic research; (2) design and test hypothesis-based, clinical therapeutic protocols; and (3) conduct cancer therapeutic research in team research settings to expedite the translation of basic research discoveries into patient-oriented therapeutic cancer research. This Program Announcement replaces PAR-03-083.
The PA will use the NIH Mentored Clinical Scientist Development K12 Program Award.
For more information see http://cri.nci.nih.gov/4abst.cfm?initiativeparfa_id=2020
Inquiries: Dr. Lester S. Gorelic, email@example.com